Post-marketing safety concerns with rimegepant based on a pharmacovigilance study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Post-marketing safety concerns with rimegepant based on a pharmacovigilance study ; volume:25 ; number:1 ; day:7 ; month:10 ; year:2024 ; pages:1-11 ; date:12.2024
The journal of headache and pain ; 25, Heft 1 (7.10.2024), 1-11, 12.2024
- Classification
-
Soziale Probleme, Sozialdienste, Versicherungen
- Creator
-
Hu, Jia-Ling
Wu, Jing-Ying
Xu, Shan
Qian, Shi-Yan
Jiang, Cheng
Zheng, Guo-Qing
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s10194-024-01858-4
- URN
-
urn:nbn:de:101:1-2412242105448.395718890546
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hu, Jia-Ling
- Wu, Jing-Ying
- Xu, Shan
- Qian, Shi-Yan
- Jiang, Cheng
- Zheng, Guo-Qing
- SpringerLink (Online service)
Other Objects (12)
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient?
Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic
Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Big data, medicines safety and pharmacovigilance
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data
Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient?
Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic
Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Big data, medicines safety and pharmacovigilance
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data
Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient?
Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic
Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Big data, medicines safety and pharmacovigilance
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data